Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Collin M. Blakely, David M. Jablons, Matthew A. Gubens et al.|Journal of Clinical Oncology|2024

Cited by 65